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Abstract
The leaves of the olive plant (Olea europaea) are rich in polyphenols, of which oleuropein and hydroxytyrosol (HT) are most charac-
teristic. Such polyphenols have been demonstrated to favourably modify a variety of cardiovascular risk factors. The aim of the present
intervention was to investigate the influence of olive leaf extract (OLE) on vascular function and inflammation in a postprandial setting
and to link physiological outcomes with absorbed phenolics. A randomised, double-blind, placebo-controlled, cross-over, acute interven-
tion trial was conducted with eighteen healthy volunteers (nine male, nine female), who consumed either OLE (51 mg oleuropein; 10 mg
HT), or a matched control (separated by a 4-week wash out) on a single occasion. Vascular function was measured by digital volume pulse
(DVP), while blood collected at baseline, 1, 3 and 6 h was cultured for 24 h in the presence of lipopolysaccharide in order to investigate
effects on cytokine production. Urine was analysed for phenolic metabolites by HPLC. DVP-stiffness index and ex vivo IL-8 production
were significantly reduced (P,0·05) after consumption of OLE compared to the control. These effects were accompanied by the excretion
of several phenolic metabolites, namely HT and oleuropein derivatives, which peaked in urine after 8–24 h. The present study provides the
first evidence that OLE positively modulates vascular function and IL-8 production in vivo, adding to growing evidence that olive phenolics
could be beneficial for health.
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Consumption of a ‘Mediterranean diet’ has been associated
with increased longevity and a decreased risk of chronic dis-
eases, including CVD, compared with other types of diet(1).
These effects are attributed, in part, to the olive oil (OO) com-
ponent of the diet(2). Indeed, research comparing refined
v. extra virgin OO has highlighted the biological effects of
the polyphenols contained within the water-soluble frac-
tion(3), in addition to other biologically active compounds
such as phytosterols and lipid-soluble vitamins. The presence
of these compounds in OO may underpin a degree of its
health-promoting properties, relative to similar MUFA-rich
oils(4). Compared to OO, the leaves of the olive plant (Olea
europaea) contain similar phenolics, although at significantly
higher concentrations than that of the olive fruit and derived
oil (1450 mg total phenolics/100 g fresh leaf(5) v. 110 mg/
100 g fruit(6) and 23 mg/100 ml extra virgin OO7). The most
abundant phenolic compounds present in the leaves are
verbascoside, apigenin-7-glucoside, luteolin-7-glucoside,
hydroxytyrosol (HT), tyrosol and the secoiridoid, oleuropein
(see Fig. 1), with secoiridoids being uniquely present in
plants of the Olearaceae family(8).
Anecdotally, olive leaf has been reported useful in treating a
range of medical conditions(9). Animal and in vitro data have
suggested a wide array of bioactive properties for phenolic-rich
olive leaf extract (OLE), including hypotensive(10), anti-
oxidant(11), anti-inflammatory(12), hypoglycaemic(11), lipid-
lowering(13) and vasoactive(14) effects, many of which have
been successfully replicated in human studies, leading to the con-
clusion that chronic OLE supplementation has the potential to
modify CVD risk (for a review see Lockyer et al.(15)). Phenolic-
rich OO has been reported to improve vascular function
relative to phenolic-poor OO, postprandially(16,17). However,
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data pertaining to the influence of OLE on vascular function are
currently lacking. In the present study, we address this by deter-
mining the extent to which OLE intake influences two measures
of CVD risk(18): arterial stiffness (assessed using digital volume
pulse (DVP)) and inflammatory status in a postprandial setting.
With respect to the latter, acute intakeofOO,with ahighphenolic
content, has been shown to repress the expression of several
pro-inflammatory genes in vivo, including the cytokines IL-6
and IL-1b(19), though knowledge regarding the effects of OLE
on inflammation is very limited.
Notably, if phenolic components are to mediate the actions
of OO and OLE on vascular function and inflammatory
processes in vivo, it is necessary that they are absorbed into
the circulation. While absorption of phenolics following OO
intake has been extensively explored(20), only two
studies(21,22) using OLE have been conducted, and direct com-
parisons of specific absorption/metabolism profiles between
OLE and OO cannot be made because of the presence of
different phenolics, their relative concentrations and food
matrix effects(23). As such, in the present study, we aim to
assess the absorption and metabolism of polyphenols from
OLE, in addition to the physiological outcomes, in order to
build a greater understanding of the ‘cause-and-effect’
relationship between OLE intake and potential biological
effects.
Experimental methods
Study population
Healthy male and female subjects were recruited from the
University of Reading and the surrounding area via email
and poster advertisements in May 2011. Smokers, those with
alcohol consumption of more than 21 units/week, or those
with any dietary restrictions, including vegetarians and those
on weight-reduction diets, were excluded. Individuals who
had suffered significant illness in the previous 12 months, or
had gastrointestinal, blood-clotting or metabolic disorders,
and females who were pregnant or breastfeeding were also
excluded. Subjects had not taken antibiotics in the previous
3 months and were not taking any lipid-modifying or
blood-clotting medication, vitamin, mineral and/or fish oil
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Fig. 1. Most abundant phenolics present in olive leaf.
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supplements at the time of completing the study. Potential
subjects underwent a screening process and individuals with
blood pressure .150/90 mmHg; Hb ,125 g/l for men and
,110 g/l for women; g-glutamyl transferase .1·3mkat/l or
cholesterol .6·5 mmol/l were excluded from the study.
Twenty suitable subjects were identified and recruited into
the study. Two subjects completed one study visit and were
lost to follow up; therefore, eighteen subjects completed the
study. Based on a medium effect size with respect to stiffness
index (a difference of 0·30 m/s) and population standard devi-
ation (0·30 m/s), we retrospectively calculate that a sample
size of fifteen participants would provide considerable
power (0·97); therefore, we conclude that our sample size of
eighteen provides ample statistical power for detecting a
change in digital volume pulse-stiffness index (DVP-SI). Base-
line characteristics of the subjects are detailed in online
Supplementary Table S1.
Study design
The study was a double-blind, randomised, controlled, cross-
over trial (Clinicaltrials.gov ID: NCT01479699) conducted
according to the guidelines laid down in the Declaration of
Helsinki. All procedures involving human subjects were
approved by the University of Reading Research Ethics Com-
mittee (UREC 11/30). Written, informed consent was obtained
from all subjects. Eighteen subjects (nine male, nine female)
aged 19–40 years completed two clinical visits at the Hugh
Sinclair Nutrition Unit, University of Reading, approximately
4 weeks apart between June and September 2011. Female sub-
jects completed both visits during the same phase of their
menstrual cycle in an attempt to control for any possible
effects of hormones on vascular function(24). Subjects were
asked to consume a low polyphenol diet (devoid of tea,
coffee, fruit, vegetables, alcoholic beverages, cocoa, whole-
grain and avoiding all olive-containing products in particular)
for 24 h before the start of each study day and remained on
this diet until after the last urine sample was collected. Compli-
ance was confirmed by the HPLC analysis of baseline urine
samples. Subjects arrived at the clinical unit in a 12-h fasted
state. A cannula was inserted into the arm and a baseline
blood sample collected. Subjects ingested either four capsules
containing OLE or four control capsules as suggested by the
product manufacturer. Blood samples were collected at base-
line and 1, 3 and 6 h after capsule ingestion. Vascular function
was measured by PCA2 Pulse Trace (Micromedical) to obtain
DVP at baseline and 0·5, 1, 1·5, 2, 3, 4, 6 and 8 h after capsule
ingestion. Urine was collected at baseline, 0–4, 4–8 and
8–24 h after capsule consumption. Samples were centrifuged
at 1800 g, 48C for 10 min and frozen at 2808C until analysis.
The total volume of urine produced during each time period
was recorded. Subjects were provided with a standard low-
fat lunch of low phenolic content (one ham sandwich and
one low-fat cheese sandwich on white bread with very-low-
fat margarine and a very-low-fat yoghurt) after the 4-h
sample collection and a meal of low phenolic content
(chicken, ham and mashed potato) after the 8-h samples.
Low-nitrate mineral water (Buxton) was provided to subjects
during the whole intervention period as required.
Test products
Four OLE capsules contained a total of 1600 mg OLE (400 mg
per capsule in 672·5 mg safflower oil) delivering a total of
51·12 mg oleuropein and 9·67 mg HT, as verified by two inde-
pendent laboratories at Southern Cross University, Australia,
and The Cawthron Institute, New Zealand. The full phenolic
profile can be found in Table 1. Control capsules each con-
tained 900 mg safflower oil and were identical in size and
appearance to OLE capsules. All capsules were provided by
Comvita New Zealand Limited and product safety was
assessed as previously detailed(25).
Measurement of vascular function
Subjects were asked to rest supine during DVP measurements.
The DVP was obtained by photoplethysmography of the
index finger using the PulseTrace PCA2 system to calculate
stiffness index (DVP-SI). The Pulse Trace is operator indepen-
dent and very reproducible. Stiffness index has been found
to be positively correlated with cardiovascular risk factors
including age, blood pressure, waist:hip ratio and carotid
thickness(26). Stiffness index values are sensitive to small
changes in vascular tone induced by vasodilators(27) and are
strongly correlated with central pulse-wave velocity, a recog-
nised measure of arterial stiffness.
Urinary phenolic analysis
Bioavailability of phenolic compounds present in OLE was
assessed by HPLC analysis of urine. Before analysis, the
samples were subjected to b-glucuronidase treatment (an
enzyme that also has sulfuronidase activity) in order to
cleave glucuronide and sulphate moieties, yielding polyphe-
nol aglycones for detection by HPLC. As such, peaks identified
by HPLC represent the sum of excretion of pure compounds
and all conjugates (e.g. the presence of HT aglycone and
any HT glucuronides and sulphates would be indicated by
the HT peak). After centrifugation (2 min at 13 000 g), urine
samples were mixed in a 1:1 ratio with 0·05 M-ammonium
Table 1. Phenolic content of olive leaf extract capsules
Compound Content in four capsules (mg)
Oleuropein 51·124
Hydroxytyrosol 9·666
Verbascoside 0·344
Luteolin 0·249
Phenolic acids* 0·233
Rutin 0·150
Apigenin 0·046
Quercetin 0·038
Flavonoids 0·028
Kaempferol 0·021
* Calculated as caffeic acid.
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acetate buffer adjusted to pH 5 with acetic acid (final volume
0·8 ml). b-Glucuronidase (50 mg; Helix pomatia; Sigma
Aldrich) in 500ml sodium acetate buffer (0·1 M) was added
to the samples, which were then vortexed before incubation
at 378C for 90 min. After incubation, 10ml acetic acid was
added to the samples on ice. The samples were centrifuged
again at 13 000g for 2 min and 0·6 ml distilled water was
added before solid-phase extraction using a vacuum manifold
with Strata C18-E (55mm, 70A) cartridges (Phenomenex). The
cartridges were conditioned with 1 ml methanol and equili-
brated with 2 ml 0·05 M-ammonium acetate solution before
sample loading and separation under gravity. To elute pheno-
lics, the cartridges were washed with 1 ml 0·05 M-ammonium
acetate buffer and dried under vacuum for 5 min. Collection
tubes were changed and 2·5 ml ethyl acetate was added to
each cartridge. The collection tubes were taken to complete
dryness using a Speedvac system (Thermo Fisher Scientific,
Inc.). Dried extracts were reconstituted in 125ml mobile
phase A (95% water, 5% methanol, 0·1% 5 M-HCl) and vortexed
for 5min. The samples were centrifuged for 2min at 13000g,
and finally the supernatants were added to the HPLC vials.
HPLC analysis was performed to characterise and quantify
the identifiable phenolic components. Precisely 50ml of
the extracted urine sample was injected into the HPLC
system. Separation of phenolic constituents was achieved
using reverse-phase HPLC using a Nova-Pak C18 column
(4·6 £ 250 mm) (Waters) with 4mm particle size. A Waters
626 pump and 600-controller system with an auto-injector
717 and a photodiode array detector 996 linked to the Millen-
nium Software system was utilised. The temperature of the
column was maintained at 308C. The mobile phase consisted
of A: 95 % water, 5 % methanol, 0·1 % 5 M-HCl and B: 50 %
acetonitrile, 50 % water and 0·1 % HCl and was pumped
through the column at 0·7 ml/min. The following gradient
system was used (min/% B): 0/5, 50/100, 60/100, 65/5, for
detection of all compounds. The eluant was monitored by
photodiode array detection at 280 nm and the spectra of
products were obtained over the 220–600 nm range. The
following pure standard compounds were purchased from
Extrasynthese: oleuropein, HT, tyrosol, homovanillic alcohol
(HValc). 3,4-Dihydroxyphenylethanol-elenolic acid (EA, oleuro-
pein aglycone) and 3,4-dihydroxyphenylethanol-elenolic acid
dialdehyde (EDA, oleuropein aglycone di-aldehyde) were
obtained as previously described by our group(28). Calibration
curves were constructed using authentic standards (0–100mM),
and in each case were found to be linear with correlation
coefficients of .0·99. Compounds identified in the samples
were characterisedby retention times (RT) and spectral similarity
to standards. Compounds identified in urine were quantified
after adjustment for volume of urine produced.
Whole blood culture
Blood was collected into heparin tubes (Greiner BioOne Lim-
ited) at baseline and 1, 3 and 6 h after capsule consumption.
These time points were selected in an attempt to capture prob-
able peak phenolic concentrations in plasma(22). Whole blood
was immediately diluted 1/1 with Roswell Park Memorial
Institute 1640 medium (Lonza Wokingham Limited), sup-
plemented with 1 % antibiotics (Penicillin 10·000 UI/ml strep-
tomycin 10·000 UI/ml Lonza Wokingham Limited). Precisely
1·8 ml diluted blood was added to one well in a twenty-
four-well plate. Lipopolysaccharide was added to give a final
concentration of 1mg/ml. An additional well containing
1·8 ml diluted blood and 0·2 ml medium served as a control.
The plates were incubated at 378C in a 5 % CO2 atmosphere
for 24 h. After incubation, the contents of the well were
removed and centrifuged at 1000 g for 2 min. Supernatants
were collected and stored at 2808C until analysis.
Cytokine analysis
IL-1b, IL-6, IL-10, TNF-a and IL-8 concentrations were
measured in whole blood culture supernatants using a
Human base kit Panel A Fluorokine MAP (Multi-analyte Profil-
ing) ELISA (R&D Systems Europe Limited) and a Luminex 200
Analyser (Invitrogen) following standard instructions provided
by the manufacturer.
Statistical analysis
Prism (GraphPad Software) was used to analyse the data. Data
were tested for normality using a K–S test. Differences in
DVP-SI, IL-1b, IL-6, TNF-a, IL-8 and IL-10 in ex vivo whole
blood cultures by treatment were identified using a two-way
ANOVA with repeated measures. Post hoc analysis was sub-
jected to Bonferroni correction. P values less than 0·05 were
treated as significant.
Results
Vascular function
The stiffness index (DVP-SI) changed significantly from base-
line over the course of the study day (significant time effect,
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Fig. 2. Effect of olive leaf extract (OLE) on digital volume pulse-stiffness
index. Values are mean changes from baseline with their standard errors rep-
resented by vertical bars (n 18) after ingestion of 1600 mg OLE ( ) or a
control ( ) on a single occasion. Two-way ANOVA with repeated measures
revealed a significant treatment effect (P¼0·0085) and a time effect
(P¼0·0028). A colour version of this figure can be found online at http://www.
journals.cambridge.org/bjn
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F1,7 ¼ 3·23; P¼0·0028, Fig. 2). In addition, there was a highly
significant treatment effect on DVP-SI (F1,7 ¼ 7·05; P¼0·0085),
with means of 0·76 (SEM 1·63) m/s for the control group and
3·36 (SEM 1·79) m/s for the OLE group over the course of the
trial, indicating that arterial stiffness was significantly lower
over the study day after consumption of the OLE capsules
compared with the control capsules. However, post hoc anal-
ysis indicated no interaction between DVP-SI and treatment
at any individual time point. In addition, there was a trend
for OLE to attenuate the post-meal increase in arterial stiffness
(between 240 and 480 min) (P¼0·074) (Fig. 2).
Ex vivo cytokine production
Ex vivo, lipopolysaccharide-stimulated IL-8 production in
whole blood cultures (isolated from human participants on
the study) was significantly lower (F1,2 ¼ 4·7; P¼0·0326;
Fig. 3) after OLE consumption (7368 (SEM 856) pg/ml)
compared to the control (15 200 (SEM 1756) pg/ml). Post hoc
analysis revealed no interaction between treatment and any
individual time point. There was no significant effect of
treatment on ex vivo production of IL-1b, IL-6, TNF-a or
IL-10 (data not shown).
Bioavailability
Analysis of urine samples by HPLC indicated the presence
of HT (RT: 8·6 min), tyrosol (RT: 14·0 min), HValc (RT:
17·3 min), EDA (RT: 30·3 min), oleuropein (RT: 38·3 min) and
EA (RT: 41·3 min) following the intake of OLE (for an example
chromatogram see online Supplementary Fig. S1). In addition,
a number of other secoiridoid peaks were observed, which
were likely to have been derived from the metabolism of
oleuropein. These compounds (four of which were observed
at RT: 31·7, 34·1, 37·2 and 38·8 min (online Supplementary
Fig. S1)), were characterised by RT and spectral similarity to
either EDA or oleuropein, although their exact identity
remains unconfirmed due to a lack of standards and/or mass
spectral data. Compounds derived from oleuropein and elut-
ing between 30 and 60 min, including EA and EDA, were
grouped together and tentatively quantified as ‘oleuropein
equivalents’. HT and its conjugates were identified in urine
samples collected at 0–4, 4–8 and 8–24 h, with levels peaking
at 4–8 h (Fig. 4). HValc and its conjugates were found to
increase steadily in the urine of subjects between 0 and 8 h,
peaking between 8 and 24 h (Fig. 5). Tyrosol was identified
in the urine of one individual (see online Supplementary
Fig. S1). Finally, oleuropein equivalents were excreted steadily
over the course of the study period, peaking at 8–24 h follow-
ing OLE consumption (Fig. 6). The grouped oleuropein
metabolites represented the most abundant breakdown pro-
duct of the OLE capsules. Baseline blood samples were
devoid of any compounds of interest.
Discussion
In the present investigation, we provide evidence that acute
consumption of OLE, an alternative source of olive phenolics,
improves vascular function and reduces the production of an
inflammatory cytokine. These observations are supported by
quantitative data regarding the absorption of OLE phenolics,
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Fig. 3. Effect of olive leaf extract (OLE) on ex vivo lipopolysaccharide-
stimulated IL-8 production in whole blood cultures. Values are mean changes
from baseline with their standard errors represented by vertical bars (n 16)
after ingestion of 1600 mg OLE ( ) or a control ( ) on a single occasion.
Two-way ANOVA with repeated measures revealed a significant treatment
effect (P¼0·0326). A colour version of this figure can be found online at
http://www.journals.cambridge.org/bjn
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Fig. 4. (a) Time-dependent appearance of hydroxytyrosol (HT) and conju-
gates in urine and (b) corresponding cumulative excretion 24 h following
ingestion of olive leaf extract (OLE) capsules. Values, derived from
HPLC analysis, are means with their standard errors represented by vertical
bars (n 18) after ingestion of 1600 mg OLE, containing 51·12 mg oleuropein
and 9·67 mg HT, on a single occasion. , Baseline; , 0–4 h; , 4–8 h;
, 8–24 h.
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indicating the bioavailability of HT, tyrosol, HValc, oleuropein,
and for the first time in relation to OLE, EDA and EA and their
metabolites in urine. Specifically, OLE led to reduced arterial
stiffness, a risk factor and independent predictor for CVD(29).
Our finding is in agreement with existing data, indicating
that OO phenolics are capable of improving vascular
function(16,17), although the latter study has been called into
question because of the criticisms of the methodology(30)
and the level of OO intake (40 ml) used representing a high
intake for a single meal(31). The present study intervened
with a phenolic-rich OLE supplement, thus avoiding the
concurrent delivery of high amounts of fat and energy.
Previous studies have begun to uncover the potential
mechanism by which olive and related products may induce
vascular improvements. For example, two studies(16,17)
observed an increase in plasma nitrates and nitrites, indicating
increased levels of NO, a known vasodilator. Although we did
not measure NO metabolites in the present study, absorbed
phenolic metabolites are thought to influence NO bioavail-
ability via their potential to inhibit NAPDH-oxidase and the
production of superoxide(32). In support of this concept, a
recent study has reported that acute blueberry intake leads
to improved blood flow, which was paralleled by inhibition
of neutrophil NADPH oxidase and the appearance of
plasma phenolic metabolites(33). Indeed, HT, tyrosol and
their metabolites have significant structural homology to the
pharmacological NADPH-oxidase inhibitor apocynin(34), and
have been proposed as potent NAPDH-oxidase inhibitors in
the endothelial cells(32). In the present study, we detected var-
ious oleuropein-like metabolites in urine along with HValc
and HT in lesser amounts. In addition to supporting the phe-
nolic acid-driven mechanism of vascular effects through
NADPH oxidase inhibition, our data suggest that oleuropein
may be absorbed, something debated in the previous litera-
ture (see online Supplementary Fig. S2)(15). Notably, one
study has reported five different glucuronides of oleuropein
aglycone in urine (with no HT)(21) and another reporting pre-
dominantly glucuronidated HT and negligible oleuropein(22).
The level of oleuropein metabolites identified in urine in the
present study is in agreement with a previous ileostomy
patient study that reported substantial absorption of OO phe-
nolics (55–66 %(35)). In addition, the excretion profile of HT
suggests both small (0–4 h; absorption of free HT present in
the OLE) and large (4 h onwards; liberated HT from bacterially
metabolised oleuropein)(36). Furthermore, the appearance
of HValc is likely to result from the O-methylation of HT by
catechol-O-methyltransferase in the large intestinal gut wall
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Fig. 5. (a) Time-dependent appearance of homovanillic alcohol (HVA), a
breakdown product of hydroxytyrosol, and conjugates in urine and (b) corre-
sponding cumulative excretion 24 h after ingestion of olive leaf extract (OLE)
capsules. Values, derived from HPLC analysis, are means with their standard
errors represented by vertical bars (n 18) after ingestion of 1600 mg OLE,
containing 51·12 mg oleuropein and 9·67 mg HT, on a single occasion.
, Baseline; , 0–4 h; , 4–8 h; , 8–24 h.
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Fig. 6. (a) Time-dependent appearance of oleuropein metabolites in urine
and (b) corresponding cumulative excretion, 24 h following ingestion of olive
leaf extract (OLE) capsules. Values, derived from HPLC analysis, are means
with their standard errors represented by vertical bars (n 18) after ingestion
of 1600 mg OLE, containing 51·12 mg oleuropein and 9·67 mg HT, on a
single occasion. , Baseline; , 0–4 h; , 4–8 h; , 8–24 h.
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and/or the liver. It is possible that two of the unidentified
oleuropein-derived compounds peaks are 3,4-DHPEA-EAH2
and 3,4-DHPEA-EDAH2, which have previously been
suggested as potential metabolites of EA and EDA, respect-
ively(37). Only one previous study(22) reports quantitative
data regarding OLE metabolites in plasma, suggesting
peak plasma concentrations of 0·52 ng/ml oleuropein and
61 ng/ml HT after OLE consumption.
Evidence suggests that lipaemia induced after consumption
of high and moderate fat-containing meals causes acute vascu-
lar dysfunction(38). In the present study, our intervention meal
(containing 7·6 g fat and 48·5 g carbohydrate) caused an
increased DVP-SI, peaking at 480 min. However, there was a
trend in our data suggesting that intake of OLE may attenuate
the postprandial vascular impairment. Our data reflect pre-
vious observations that phenolic-rich vegetables are capable
of attenuating high-fat-meal-induced increases in blood press-
ure in the presence of L-arginine, thus restoring vascular
homeostasis(39). Postprandial lipaemia has also been associ-
ated with an increase in circulating inflammatory cytokines(40).
In the present study, increases in cytokines were not
observed, probably due to the relatively low fat content of
the meal. However, postprandial activation and recruitment
of neutrophils appears to be associated with a concomitant
increase in IL-8, hydroperoxide and endothelial dysfunction(41).
As such, the reduction in ex vivo production of IL-8 by an
acute dose of OLE may at least partly explain the post-inges-
tion reduction in DVP-SI.
The anti-inflammatory effects of olive phenolics have been
previously indicated(12,13,42), indeed, OLE is used as an ingre-
dient in a patented haemorrhoid treatment(43). In the present
study, OLE specifically modulated ex vivo production of
IL-8, a low-molecular-weight cytokine produced by a variety
of cell types, including monocytes and endothelial cells(44).
We suggest that the present ex vivo work, which used samples
derived from the postprandial intervention, is reliable as the
OLE metabolites generated in vivo were present in the
blood used and therefore this is arguably representative of
the physiological scenario. It has been postulated that IL-8
plays a key role in the development of atherosclerosis along
with other pro-inflammatory cytokines(45). IL-8 may also desta-
bilise existing atherosclerotic plaques by down-regulation of
tissue inhibitors of metalloproteinases(46). Although cytokines
are not held in the same regard as other biomarkers such as
blood pressure and plasma lipids(47), circulating levels of
IL-8 have been positively associated with future CVD risk(48).
It has been hypothesised that endogenously produced
reactive oxygen species directly induce the transcription and
translation of IL-8(49). OLE phenolics may selectively inhibit
IL-8 production via their redox activity(11), in particular
oleuropein and HT, which contain redox-active catechol
groups. Green tea catechins and curcumin have also been
shown to specifically interfere with IL-8 gene expression
through inhibition of NF-kB activation(50). Similarly, in vitro
work has suggested that oleuropein aglycone and HT repress
vascular cell adhesion molecule 1 gene transcription by
blocking activator protein-1 and NF-kB activation(51).
The present study provides novel data regarding the positive
effects of acute consumption of olive (poly)phenols on the
human vasculature. Our data support the concept that OLE
positively modulates vascular function and IL-8 production
in vivo via the actions of absorbed phenolic metabolites and
add to growing evidence that olive phenolics could be bene-
ficial for vascular health. Our data also provide further infor-
mation relating to the absorption and metabolism of OLE
phenolics per se, suggesting that oleuropein metabolites do
enter the circulation. One caveat is that the product used has
not been completely characterised; in other words, that other
bioactives previously identified in OLE, such as minerals,
triterpenoids and squalene(52), could have been responsible
for the observed response. Nevertheless, the findings presented
here add weight to the concept that OLE could represent an
important dietary tool in lowering CVD risk.
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